LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Search

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

46.69 -1.6

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

46.5

Massimo

47.22

Metriche Chiave

By Trading Economics

Entrata

-14M

-130M

Vendite

-888K

143K

Margine di Profitto

-90,972.727

Dipendenti

437

EBITDA

33K

-129M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+71.42% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

258M

4.3B

Apertura precedente

48.29

Chiusura precedente

46.69

Notizie sul Sentiment di mercato

By Acuity

26%

74%

50 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 dic 2025, 21:08 UTC

Acquisizioni, Fusioni, Takeovers

Meta Platforms Buys AI-Device Maker Limitless

5 dic 2025, 19:39 UTC

I principali Market Mover

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5 dic 2025, 19:17 UTC

Acquisizioni, Fusioni, Takeovers

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

6 dic 2025, 16:52 UTC

Acquisizioni, Fusioni, Takeovers

As Netflix Swoops In to Buy Warner Bros., We Revisit the Studio's Long, Twisted Journey -- Barrons.com

6 dic 2025, 10:30 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Why Netflix Shareholders Aren't Thrilled to Acquire Warner Bros. -- Heard on the Street -- WSJ

6 dic 2025, 02:38 UTC

Acquisizioni, Fusioni, Takeovers

How a Netflix-Warner Deal Would Change Everything in Hollywood -- Again -- WSJ

5 dic 2025, 21:59 UTC

Acquisizioni, Fusioni, Takeovers

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5 dic 2025, 21:50 UTC

Discorsi di Mercato
Utili

Financial Services Roundup: Market Talk

5 dic 2025, 21:50 UTC

Acquisizioni, Fusioni, Takeovers

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5 dic 2025, 21:36 UTC

Discorsi di Mercato

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5 dic 2025, 21:35 UTC

Acquisizioni, Fusioni, Takeovers

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5 dic 2025, 21:26 UTC

Acquisizioni, Fusioni, Takeovers

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5 dic 2025, 21:12 UTC

Discorsi di Mercato

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5 dic 2025, 21:03 UTC

Discorsi di Mercato
Utili

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5 dic 2025, 21:01 UTC

Discorsi di Mercato

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5 dic 2025, 20:43 UTC

Acquisizioni, Fusioni, Takeovers

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5 dic 2025, 20:43 UTC

Acquisizioni, Fusioni, Takeovers

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5 dic 2025, 20:42 UTC

Acquisizioni, Fusioni, Takeovers

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5 dic 2025, 20:01 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5 dic 2025, 19:44 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

5 dic 2025, 19:44 UTC

Discorsi di Mercato

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5 dic 2025, 19:39 UTC

Discorsi di Mercato

Silver Climbs to a New Record High -- Market Talk

5 dic 2025, 19:31 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dic 2025, 18:30 UTC

Discorsi di Mercato

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5 dic 2025, 18:28 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dic 2025, 18:24 UTC

Acquisizioni, Fusioni, Takeovers

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

5 dic 2025, 18:20 UTC

Discorsi di Mercato

Baker Hughes Reports Higher U.S. Rig Count -- Market Talk

5 dic 2025, 18:11 UTC

Discorsi di Mercato

The Tale of Two Canadian Employment Indicators -- Market Talk

5 dic 2025, 17:48 UTC

Discorsi di Mercato

Canadian Youth Unemployment Rate Cools -- Market Talk

5 dic 2025, 17:44 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Equities Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

71.42% in crescita

Previsioni per 12 mesi

Media 80 USD  71.42%

Alto 108 USD

Basso 45 USD

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

15 ratings

14

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

50 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat